

Efficacy and safety of of tribendimidine against hookworm infections in children: a randomized controlled trial

Submission date 19/05/2017	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 19/05/2017	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 04/01/2019	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Parasitic worms are organisms that live in the intestine and feed off their living hosts. There are many types of parasitic worms, including the hookworm. They are among the most common type of infections worldwide, especially in poor and deprived communities. They are spread by eggs present in human faeces which in turn contaminate soil in areas where sanitation is poor. An infection can cause malnutrition, physical and mental retardation, and reduced work performance in older age. Few drugs are available which are widely used in the treatment of parasitic worm infections and drug resistance is a growing problem. Tribendimidine is a broad-spectrum anti-parasitic worm drug which has been developed in China. The aim of this study is to find out the best dose of this drug to give to children with hookworm infections.

Who can participate?

Children aged between six and twelve years who have hookworm eggs in their stool.

What does the study involve?

Participants are randomly allocated to one of five groups. Those in the first group receive a single dose of 100 mg tribendimidine. Those in the second group receive a single dose of 200 mg tribendimidine. Those in the third group receive a split 200 mg tablet of tribendimidine. Those in the next group receive a single dose of a placebo (dummy drug). 21 days after receiving the treatment, participants provide a stool sample which is then tested for signs of parasitic worm eggs. Participants are also interviewed before treatment, 3 and 24 hours after treatment about whether they have experienced any side effects.

What are the possible benefits and risks of participating?

All participants benefit from receiving a clinical examination and hookworm infection treatment. STHs. All participating children remaining positive for hookworm at the end of the study will be treated with another medication (according to WHO recommendations). There are no notable risks involved with participating.

Where is the study run from?
Rubino Health Center (Cote d'Ivoire)

When is the study starting and how long is it expected to run for?
January 2017 to December 2017

Who is funding the study?
European Research Council (Belgium)

Who is the main contact?
Professor Jennifer Keiser
jennifer.keiser@unibas.ch

Contact information

Type(s)
Scientific

Contact name
Prof Jennifer Keiser

Contact details
Swiss Tropical and Public Health Institute
Socinstrasse 57
Basel
Switzerland
4051
+41 612 848 218
jennifer.keiser@unibas.ch

Additional identifiers

Protocol serial number
v.1.02

Study information

Scientific Title
Efficacy and safety of ascending dosages of tribendimidine against hookworm and concomitant soil-transmitted helminth infections in children: a randomized controlled trial

Study objectives
The aim of this study is to compare the efficacy and safety of three oral tribendimidine dosages (100 mg, 200 mg and 400 mg) versus placebo in school-aged children infected with hookworm and to measure tribendimidine disposition using dried blood spot technology.

Ethics approval required
Old ethics approval format

Ethics approval(s)

1. Ethics committee of Northwestern and Central Switzerland (EKNZ) 03/04/2017, ref: 2017-00139
2. Ministere de la Sante et de hygiene publique, comite nationa d'ethique de la recherche, 17/04/2017, ref: 053/IMSHP/CNER-kp

Study design

Single blind randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hookworm infection

Interventions

Current interventions as of 25/07/2017:

Single, oral tribendimidine 100, 200 and 400 mg and placebo.

Patients will be randomized using block randomization to one of four groups.

Intervention group 1: Participants receive a single dose of oral tribendimidine 100 mg

Intervention group 2: Participants receive a single dose of oral tribendimidine 200 mg

Intervention group 4: Participants receive a single dose of oral tribendimidine 400 mg

Control group: Participants receive a single dose of a placebo

Follow up will be conducted for all treatment arms 21 days after treatment.

Previous interventions:

Single, oral tribendimidine 100, 200 and 400 mg and placebo.

Patients will be randomized using block randomization to one of four groups.

Intervention group 1: Participants receive a single dose of oral tribendimidine 100 mg

Intervention group 2: Participants receive a single dose of oral tribendimidine 200 mg

Intervention group 3: Participants receive a single dose of oral tribendimidine 200 mg split tablet

Intervention group 4: Participants receive a single dose of oral tribendimidine 400 mg

Control group: Participants receive a single dose of a placebo

Follow up will be conducted for all treatment arms 21 days after treatment.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Tribendimidine

Primary outcome(s)

Cure rate (conversion from being egg positive pre-treatment to egg negative post-treatment) against hookworm infection will be assessed using the quadruple Kato-Katz method at 21 days post-treatment.

Key secondary outcome(s)

1. Egg reduction rate against hookworm infection will be assessed using the quadruple Kato-Katz method at 21 days post-treatment
2. Cure and egg reduction rate against concomitant soil-transmitted helminths will be assessed using the quadruple Kato-Katz method at 21 days post-treatment
3. Safety will be assessed with evaluation of adverse events of the treated subjects based on interviews at 3 and 24 hours after treatment
4. Pharmacokinetic parameters: drug concentrations will be measured with a validated LC/MS method at baseline, 2, 3, 4, 5, 6, 7, 7.5, 8.5 and 24 hours post-dosing

Completion date

31/12/2017

Eligibility**Key inclusion criteria**

1. Written informed consent signed by parents and/or legal representative; and oral assent by child
2. Able and willing to be examined by a study physician at the beginning of the study
3. Able and willing to provide two stool samples at the beginning (baseline) and approximately three weeks after treatment (follow-up)
4. Positive for hookworm eggs in the stool
5. Absence of major systemic illnesses, e.g. diabetes, severe anemia, clinical malaria as assessed by a medical doctor, upon initial clinical assessment
6. No known or reported history of chronic illness as cancer, diabetes, chronic heart, liver or renal disease
7. No recent anthelmintic treatment (within past 4 weeks)
8. No known allergy to tribendimidine
9. Age range is 6-12 years old

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

6 years

Upper age limit

12 years

Sex

All

Key exclusion criteria

1. No written informed consent by parents and/or legal representative
2. Presence of major systemic illnesses, e.g. diabetes, severe anemia, clinical malaria as assessed by a medical doctor, upon initial clinical assessment
3. History of acute or severe chronic disease
4. Recent use of anthelmintic drug (within past 4 weeks)
5. Attending other clinical trials during the study
6. Negative diagnostic result for hookworm eggs in the stool

Date of first enrolment

25/05/2017

Date of final enrolment

30/09/2017

Locations**Countries of recruitment**

Côte d'Ivoire

Study participating centre

Rubino Health Center

Rubino

Côte d'Ivoire

0000

Sponsor information**Organisation**

Swiss Tropical and Public Health Institute

ROR

<https://ror.org/03adhka07>

Funder(s)**Funder type**

Government

Funder Name

European Research Council

Alternative Name(s)

The European Research Council, ERC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from jennifer.keiser@unibas.ch

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	27/08/2018		Yes	No
Results article	results	16/08/2019		Yes	No
Basic results		04/01/2019	04/01/2019	No	No